Houston Rx recalled 64 tirzepatide/niacinamide vials

FDA's public Enforcement Report lists event 99990 for Houston Rx LLC, 15340 Vantage Pkwy E Ste 220, Houston, TX 77032-1901. The recall is voluntary, firm-initiated, and Ongoing, with nationwide U.S. distribution. Initiation date: 25 September 2026. Classification, internet posting, report, and determination dates: 13 October 2026. Enforcement report date: 21 October 2026. First notification: Combination. No telehealth brand is named. openFDA returned no match for event 99990 on 22 October 2026. Its newest tirzepatide report date is still 14 October 2026.

D-0040-2027 is Class II: Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, 64 vials, lot TZN-080326-20/2-2, beyond-use date 12/01/2026, for lack of assurance of sterility. The product line uses 15430 Vantage Parkway E STE 220. The same event's D-0041-2027 is 7 vials of sermorelin 1 mg/mL, lot SER-081726-1-10, beyond-use date 10/01/2026, for lack of process control. FDA defines Class II as use or exposure that may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA's 1 April 2026 page uses semaglutide plus cyanocobalamin as an example of an essentially a copy. That example is not this lot. An 18 September 2026 warning letter names tirzepatide/niacinamide at Empower Pharmacy, a different firm. Ask which pharmacy fills the prescription, then match the label.

What this means for prices we track

The catalog records price, not the dispensing pharmacy. This note does not say any listed provider used Houston Rx LLC or lot TZN-080326-20/2-2. SnagRX, Embody, and MEDGm's terms, opened 22 October 2026, name Red Rock or RedRock Pharmacy, Health Warehouse, Precision Medicine, and Triad Rx. None of those names is Houston Rx LLC. The cost comparison lists the other opened pages, which do not name a pharmacy. bmiMD returned HTTP 403. MyDrHank returned no pharmacy text.

Compounded tirzepatide: 13 providers, low $129, median $299, high $399, checked 21 October 2026 to 22 October 2026. That cost note separates month-one, continuing, and prepaid prices. The 14 October recall note covers Carolina Infusion and Apothecary Pharma. The Price Index uses the same continuing-price rule.